Current Status and Future Prospects of Kidney Cancer Treatment
Posted: Tuesday, May 7, 2019
A review, published in the International Journal of Urology, evaluated the current status and future prospects of adjuvant and neoadjuvant therapeutic strategies in localized and locally advanced renal cell carcinoma. Sean W. Berquist, MD, MS, of Stanford University, California, and colleagues concluded, if feasible, patients should enroll in clinical trials prior to treatment due to conflicting clinical trial results. The safety and efficacy of systemic therapy for patients with renal cell carcinoma remain areas of active investigation.
The authors conducted a comprehensive literature search of keywords using PubMed, MEDLINE, Cochrane Central Register of Controlled Trials, the American Society of Clinical Oncology, and ClinicalTrials.gov. The review included reported and published adjuvant trials (n = 6), neoadjuvant trials (n = 15), ongoing adjuvant trials (n = 7), ongoing neoadjuvant trials (n = 6), and an ongoing hybrid adjuvant/neoadjuvant trial (n = 1). All publications included patients with localized renal cell carcinoma.
Although the U.S. Food and Drug Administration (FDA) recently approved sunitinib as the first adjuvant agent based on results from the Sunitinib Treatment of Renal Adjuvant Cancer study, results of adjuvant therapy in phase III trials have been mixed, the authors noted. Large-scale, randomized clinical trial data for neoadjuvant therapy are unavailable. However, findings from phase II trials suggest presurgical tumor reduction may benefit some patients with renal cell carcinoma.
“The advent of immunomodulation through checkpoint inhibition represents an exciting horizon for adjuvant and neoadjuvant strategies,” the study authors concluded.
Disclosure: The study authors’ disclosure information may be found at wiley.com.